Apellis Pharmaceuticals, Inc.

BIT:1APLS Stock Report

Market Cap: €4.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Apellis Pharmaceuticals Management

Management criteria checks 3/4

Apellis Pharmaceuticals' CEO is Cedric Francois, appointed in Sep 2009, has a tenure of 16.67 years. total yearly compensation is $13.34M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 1.14% of the company’s shares, worth €51.34M. The average tenure of the management team and the board of directors is 4.8 years and 10.8 years respectively.

Key information

Cedric Francois

Chief executive officer

US$13.3m

Total compensation

CEO salary percentage6.16%
CEO tenure16.7yrs
CEO ownership1.1%
Management average tenure4.8yrs
Board average tenure10.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Cedric Francois's remuneration changed compared to Apellis Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$133m

Dec 31 2025US$13mUS$822k

US$22m

Sep 30 2025n/an/a

US$45m

Jun 30 2025n/an/a

-US$228m

Mar 31 2025n/an/a

-US$224m

Dec 31 2024US$11mUS$793k

-US$198m

Sep 30 2024n/an/a

-US$250m

Jun 30 2024n/an/a

-US$333m

Mar 31 2024n/an/a

-US$417m

Dec 31 2023US$10mUS$735k

-US$529m

Sep 30 2023n/an/a

-US$606m

Jun 30 2023n/an/a

-US$657m

Mar 31 2023n/an/a

-US$691m

Dec 31 2022US$9mUS$681k

-US$652m

Sep 30 2022n/an/a

-US$634m

Jun 30 2022n/an/a

-US$638m

Mar 31 2022n/an/a

-US$702m

Dec 31 2021US$9mUS$647k

-US$746m

Sep 30 2021n/an/a

-US$520m

Jun 30 2021n/an/a

-US$460m

Mar 31 2021n/an/a

-US$360m

Dec 31 2020US$9mUS$619k

-US$345m

Sep 30 2020n/an/a

-US$536m

Jun 30 2020n/an/a

-US$470m

Mar 31 2020n/an/a

-US$423m

Dec 31 2019US$4mUS$560k

-US$305m

Compensation vs Market: Cedric's total compensation ($USD13.34M) is above average for companies of similar size in the Italian market ($USD2.09M).

Compensation vs Earnings: Cedric's compensation has been consistent with company performance over the past year.

CEO

Cedric Francois (53 yo)

16.7yrs
Tenure
US$13,342,739
Compensation

Dr. Cedric Francois, M.D., Ph.D. is Co-Founder and Chairman of Liberate Medical, Inc. He serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and ha...

Leadership Team

NamePositionTenureCompensationOwnership
Cedric Francois
Co-Founder16.7yrsUS$13.34m1.14%
€ 51.3m
Timothy Sullivan
CFO & Treasurer8.6yrsUS$4.98m0.084%
€ 3.8m
David Watson
General Counsel & Secretary12.3yrsUS$4.73m0.071%
€ 3.2m
Kelley Boucher
Chief People Officer1.3yrsUS$4.53m0%
€ 0
Caroline Baumal
Chief Medical Officer3.3yrsUS$4.62m0.028%
€ 1.2m
Pascal Deschatelets
Co-Founder & Chief Scientific Officer16.7yrsUS$3.08m0.88%
€ 39.9m
James Chopas
VP, Corporate Controller & Chief Accounting Officer4.8yrsno data0.018%
€ 825.8k
Eva Stroynowski
Head of Investor Relationsno datano datano data
Peter Hillmen
Head of Hematology Engagement & Member of PNH Scientific Advisory Board4yrsno datano data
Nur Nicholson
Chief Technical Operations Officerno dataUS$3.02m0.027%
€ 1.2m
David Acheson
Executive Vice President of Commercialno datano datano data
Mark DeLong
Chief Business & Strategy Officer3.3yrsno data0.090%
€ 4.0m
4.8yrs
Average Tenure
54.5yo
Average Age

Experienced Management: 1APLS's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Hillmen
Head of Hematology Engagement & Member of PNH Scientific Advisory Board10.8yrsno datano data
Philip J. Rosenfeld
Member of AMD Scientific Advisory Board10.8yrsno datano data
Gabriel Coscas
Member of AMD Scientific Advisory Board10.8yrsno datano data
Johanna Seddon
Member of AMD Scientific Advisory Board10.8yrsno datano data
Robert Brodsky
Member of PNH Scientific Advisory Board10.8yrsno datano data
Michael Yeadon
Member of Pulmonology Scientific Advisory Board10.8yrsno datano data
Marsha Wills-Karp
Member of Pulmonology Scientific Advisory Boardno datano datano data
Carl Atkinson
Member of Pulmonology Scientific Advisory Board10.8yrsno datano data
Claudia Kemper
Member of Pulmonology10.8yrsno datano data
Susan Lea
Member of Pulmonology10.8yrsno datano data
Toby Maher
Member of Pulmonology Scientific Advisory Board10.8yrsno datano data
Dave Singh
Member of Pulmonology Scientific Advisory Board10.8yrsno datano data
10.8yrs
Average Tenure

Experienced Board: 1APLS's board of directors are seasoned and experienced ( 10.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 04:10
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apellis Pharmaceuticals, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Colleen KusyBaird
Eliana MerleBarclays